

3<sup>rd</sup> February, 2023

To,  
The Manager - Corporate Relationship Dept.  
BSE Limited  
P. J. Towers, Dalal Street  
Fort, Mumbai - 400 001

To,  
The Manager - Corporate Compliance  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot No.C-1,  
G Block, BKC, Bandra (E),  
Mumbai 400 051

**Scrip Code: BSE - 524500**

**Scrip Code: NSE - KILITCH**

**Sub: Intimation of the Board Meeting to consider the Financial Results for the quarter ended 31<sup>st</sup> December, 2022**

Dear Sir,

Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the Meeting of the Board of Directors of the Company will be held on Tuesday, 14<sup>th</sup> February, 2023 inter-alia to consider and approve the Standalone and Consolidated un-audited Financial Results of the Company for the quarter ended 31<sup>st</sup> December, 2022.

Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with Circular No. LIST/COMP/01/2019-20 dated 2<sup>nd</sup> April, 2019 issued by BSE and Circular Reference no. NSE/CML/2019/11 dated 2<sup>nd</sup> April, 2019 issued by NSE, the Trading Window has been closed with effect from 1<sup>st</sup> January, 2023 and will re-open 48 hours after said financial results are disclosed to the Stock Exchanges.

We request you to kindly take the same on record and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

MUKUND  
PRATAPRAI MEHTA

**Mukund Mehta**  
Managing Director

Digitally signed by MUKUND PRATAPRAI MEHTA  
DN: cn=MUKUND PRATAPRAI MEHTA, o=KILITCH DRUGS (INDIA) LIMITED, ou=KILITCH DRUGS (INDIA) LIMITED, email=MUKUND@KILITCH.COM, c=IN

